Skip to content
Cloudbreak Therapeutics logo — Leading the future of eye care with efficient drug repurposi...

Cloudbreak Therapeutics

Leading the future of eye care with efficient drug repurposing and fast-tracked clinical advancements.

Founded 2015 11-50 employees Series C Total: $171.22M Biotechnology, Health Care

General Information

Company Name Cloudbreak Therapeutics
Founded Year 2015
Employees 11-50
Industries Biotechnology, Health Care
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Cloudbreak Therapeutics. To contact Cloudbreak Therapeutics, visit cloudbreaktherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cloudbreak Therapeutics compare?

A PDF of Cloudbreak Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cloudbreak Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cloudbreak Therapeutics

Cloudbreak Therapeutics is a clinical-stage biotechnology company pioneering the future of eye care through efficient drug repurposing and fast-tracked clinical advancements. Established in 2015, the company focuses on ocular drug development, employing a capital-efficient business model based on VIC + 505b(2). This approach involves repurposing approved systemic drugs for ocular delivery to effectively treat various eye diseases. The company’s strategy enables the rapid advancement of drug candidates, moving swiftly through proof-of-concept (POC) Phase II clinical trials. Subsequently, they out-license global rights for Phase III clinical trials, product registration, and commercialization. Cloudbreak Therapeutics is fully engaged in the pharmaceutical development ecosystem, optimizing capital for drug development by partnering with contract research organizations (CRO) for non-clinical, CMC, and clinical development. In a significant milestone, Cloudbreak Therapeutics secured a substantial $130.00M Series C investment on January 1, 2022. The investment consortium included prominent firms such as EFung Capital, CDH Investments, CCB International, Dyee Capital, Grand Pharma, Industrial Securities Capital, CDF-Capital, Yuejun Investment, Yingke Capital, and ShenZhen GTJA Investment Group. This strategic investment underscores the confidence and support from leading investors in the company's innovative approach and its potential to revolutionize eye care. With a clear focus on biotechnology and healthcare industries, Cloudbreak Therapeutics stands poised to drive significant advancements in ocular drug development and positively impact the future of eye care.

Business keywords: ocular drug development, clinical-stage company, drug repurposing, efficient capital model, VIC + 505b(2), proof-of-concept trials, contract research organizations, pharmaceutical development, CMC, out-licensing, global rights, commercialization, eye care, systemic drugs

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $130.00M 10
EFung Capital, CDH Investments +8
01 Jan 2022
Series B $25.40M -
17 Apr 2020
Series A $15.82M -
26 Oct 2018

Cloudbreak Therapeutics Alternatives & Competitors

View All Alternatives
Cloudbreak Therapeutics vs

TetraLogic Pharmaceuticals (Nasdaq: TLOG) is a clinical-stage biopharmaceutical company focused on d...

Convertible Note
10 employees
Biotechnology, Health Care
Cloudbreak Therapeutics vs

Acadia is trailblazing breakthroughs in neuroscience to elevate life.

Post-IPO Equity
1028 employees
Biotechnology, Health Care
Cloudbreak Therapeutics vs
GLG Pharma
GLG Pharma United States

Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's Compounds...

Venture round
3 employees
Biotechnology, Health Care

FAQ About Cloudbreak Therapeutics

Leading the future of eye care with efficient drug repurposing and fast-tracked clinical advancements.
Cloudbreak Therapeutics was founded in 2015.
Cloudbreak Therapeutics operates in Biotechnology and Health Care. Its work centres on ocular drug development, clinical-stage company, drug repurposing and efficient capital model.
Cloudbreak Therapeutics has approximately 11-50 employees.
Cloudbreak Therapeutics has completed 3 funding rounds, raising a total of $171.22M. The latest funding stage is Series C.
Top alternatives and competitors to Cloudbreak Therapeutics include Tetralogic Pharmaceuticals, Acadia Pharmaceuticals, GLG Pharma, Evotec, ASLAN Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cloudbreak Therapeutics and Tetralogic Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cloudbreak Therapeutics, https://bouncewatch.com/company/cloudbreak-therapeutics, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout